Literature DB >> 15007160

Understanding co-morbidities affecting children with epilepsy.

John M Pellock1.   

Abstract

Co-morbid conditions frequently occur in childhood epilepsy and may significantly affect epilepsy and its treatment. Similarly, epilepsy and antiepileptic drugs (AEDs) may affect these associated conditions. Co-morbidities that have a significant association with childhood epilepsy include attention-deficit/hyperactivity disorder, autism, developmental disabilities, accidental injury, migraine, and depression/anxiety. Understanding the interrelationships among co-morbidities, epilepsy, and their treatments is essential to optimal management of pediatric patients. Treatment should be individualized with consideration for specific co-morbidities and concomitant medications. Key treatment goals are to achieve seizure control and optimal physical and cognitive function using the simplest possible AED regimen. The clinician should consider whether an antiepileptic treatment can be chosen that also ameliorates the co-morbid condition. Newer AEDs, such as lamotrigine, topiramate, gabapentin, oxcarbazepine, and tiagabine, may benefit children with epilepsy and some co-morbid disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15007160     DOI: 10.1212/wnl.62.5_suppl_2.s17

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

Review 1.  Epilepsy in autism spectrum disorders.

Authors:  Roberto Canitano
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-24       Impact factor: 4.785

2.  Depressive behavior and selective down-regulation of serotonin receptor expression after early-life seizures: reversal by environmental enrichment.

Authors:  Sookyong Koh; Rhamy Magid; Hyokwon Chung; Christy D Stine; Dawn N Wilson
Journal:  Epilepsy Behav       Date:  2007-02       Impact factor: 2.937

3.  Benign rolandic epileptiform discharges are associated with mood and behavior problems.

Authors:  Dean P Sarco; Katrina Boyer; Shannon M Lundy-Krigbaum; Masanori Takeoka; Frances Jensen; Matt Gregas; Deborah P Waber
Journal:  Epilepsy Behav       Date:  2011-08-20       Impact factor: 2.937

Review 4.  Chronic disorders with episodic manifestations: focus on epilepsy and migraine.

Authors:  Sheryl R Haut; Marcelo E Bigal; Richard B Lipton
Journal:  Lancet Neurol       Date:  2006-02       Impact factor: 44.182

5.  A decision support framework for the discrimination of children with controlled epilepsy based on EEG analysis.

Authors:  Vangelis Sakkalis; Tracey Cassar; Michalis Zervakis; Ciprian D Giurcaneanu; Cristin Bigan; Sifis Micheloyannis; Kenneth P Camilleri; Simon G Fabri; Eleni Karakonstantaki; Kostas Michalopoulos
Journal:  J Neuroeng Rehabil       Date:  2010-06-02       Impact factor: 4.262

6.  Epilepsy in childhood and adolescence.

Authors:  Bernd A Neubauer; Stephanie Gross; Andreas Hahn
Journal:  Dtsch Arztebl Int       Date:  2008-04-25       Impact factor: 5.594

7.  Excess mortality and causes of death in autism spectrum disorders: a follow up of the 1980s Utah/UCLA autism epidemiologic study.

Authors:  Deborah Bilder; Elizabeth L Botts; Ken R Smith; Richard Pimentel; Megan Farley; Joseph Viskochil; William M McMahon; Heidi Block; Edward Ritvo; Riva-Ariella Ritvo; Hilary Coon
Journal:  J Autism Dev Disord       Date:  2013-05

8.  Obesity and overweight as CAE comorbidities and differential drug response modifiers.

Authors:  Ravindra Arya; Catherine W Gillespie; Avital Cnaan; Mahima Devarajan; Peggy Clark; Shlomo Shinnar; Alexander A Vinks; Kana Mizuno; Tracy A Glauser
Journal:  Neurology       Date:  2016-03-30       Impact factor: 9.910

9.  Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy.

Authors:  Z S Daniels; T G Nick; C Liu; A Cassedy; T A Glauser
Journal:  Neurology       Date:  2009-05-27       Impact factor: 9.910

Review 10.  Genetic variation and shared biological susceptibility underlying comorbidity in neuropsychiatry.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.